타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tecentriq (atezolizumab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | PD-L1 |
Overview Indication | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), |
Positioning Known limitation | resistance to existing therapies |
MoA Mechanism | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. |
MoA Biomarker | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Major finding | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tecentriq (atezolizumab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | PD-L1 |
Overview Indication | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), |
Positioning Known limitation | resistance to existing therapies |
MoA Mechanism | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. |
MoA Biomarker | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Major finding | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교